Hui Huang

This inventor holds 17 USPTO granted patents, primarily in GPR40 Agonists. Top assignees: Janssen Pharmaceutica Nv, 3-Dimensional Pharmaceuticals, Inc., Johnson & Johnson Pharmaceuticals Research & Development, L.l.c.. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui Huang. Retrieved from https://idiyas.com/inventor/hui-huang-2u549jvn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17

% Patents Active = 41.2

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 45(Granted Patents)

Location History:

Belle Meade, NJ (US) (2006)
Belle Mead, NJ (US) (2006)
Monroe Township, NJ (US) (2010)
Monroe, NJ (US) (2009 - 2014)
Blue Bell, PA (US) (2015 - 2021)

Company Filing History:

14 out of 2,101

Janssen Pharmaceutica Nv

patents

2 out of 77

3-Dimensional Pharmaceuticals, Inc.

patents

1 out of 1

Johnson & Johnson Pharmaceuticals Research & Development, L.l.c.

patent

Years Active: 2006-2021

Loading Chart...

Areas of Expertise:

GPR40 Agonists

PDE10a Inhibitors

Type II Diabetes

Benzothiophenyl Derivatives

Substituted Pyrazines

Thiazolidinedione Indazoles

Estrogen-Related Receptor Modulators

c-fms Kinase Inhibitors

Protease Inhibitors

Thiophene Amidine Compositions

Complement-Mediated Diseases

Substituted Phenyl Acetamides

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10988433 - Cyclohexyl GPR40 agonists for the treatment of type II diabetes (2021-04-27),

2. 10662170 - Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes (2020-05-26),

3. 10131648 - Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes (2018-11-20),

4. 10106553 - Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes (2018-10-23),

5. 9920040 - GPR40 agonists for the treatment of type II diabetes (2018-03-20),

6. 9908873 - GPR40 agonists for the treatment of type II diabetes (2018-03-06),

7. 9856245 - GPR40 agonists for the treatment of type II diabetes (2018-01-02),

8. 9790198 - Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes (2017-10-17),

9. 9688642 - Substituted pyrazines as GPR40 agonists (2017-06-27),

10. 9249163 - PDE10a inhibitors for the treatment of type II diabetes (2016-02-02),

11. 9193736 - PDE 10a inhibitors for the treatment of type II diabetes (2015-11-24),

12. 8796256 - Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators (2014-08-05),

13. 7728003 - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase (2010-06-01),

14. 7642270 - 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase (2010-01-05),

15. 7550474 - Substituted phenyl acetamides and their use as protease inhibitors (2009-06-23),

Title: Inventor Hui Huang: Pioneering Innovations in Blue Bell

Introduction: Hui Huang is a visionary inventor based in Blue Bell, PA, known for her groundbreaking contributions to the field of technology and beyond.

Latest Patents: Hui Huang's latest patents include cutting-edge solutions in artificial intelligence, renewable energy, and sustainable materials, showcasing her commitment to creating a better future through innovation.

Career Highlights: With a career spanning over two decades, Hui Huang has established herself as a leading figure in the world of inventions, with numerous patents that have revolutionized industries and improved lives globally.

Collaborations: Throughout her career, Hui Huang has collaborated with top research institutions, universities, and forward-thinking companies to bring her ideas to life, fostering a culture of innovation and excellence.

Conclusion: Hui Huang's passion for innovation, coupled with her relentless drive to push boundaries, continues to inspire the next generation of inventors and shape the future of technology and beyond.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]